title: Response to the letter to the editor by Ewenstein BM and Reininger AJ.
authors.forename: A
authors.initials: A
authors.lastname: Klukowska
authors.forename: V
authors.initials: V
authors.lastname: Komrska
authors.forename: M
authors.initials: M
authors.lastname: Jansen
authors.forename: P
authors.initials: P
authors.lastname: Laguna
mesh_terms: D019774:Blood Coagulation Factor Inhibitors / Q000097:blood*; D005169:Factor VIII / Q000037:antagonists & inhibitors*; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology*; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D014841:von Willebrand Factor / Q000627:therapeutic use*
chemical_list: D019774:Blood Coagulation Factor Inhibitors; D006490:Hemostatics; D014841:von Willebrand Factor; D005169:Factor VIII